Inflammasome Inhibitors
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 84201
Special Issue Editor
Interests: drug discovery, synthesis and structure-activity relationships of biologically active compounds; design and synthesis of multi-target drugs and NLRP3 ligands for the treatment of chronic inflammatory, neurodegenerative and autoimmune diseases. Protein targeting chimaeras (PROTACs)
Special Issue Information
Dear Colleagues,
Inflammasomes are intracellular multiprotein complexes that play a fundamental role in the immune system. Since the discovery of the NLRP3 inflammasome by Jürg Tschopp’s group in 2002, the inflammasome has attracted a great deal of interest because of its intriguing biochemical properties and potential role as a drug target.
Over the last decade, altered NLRP3 signaling has been associated to a range of different pathogenic conditions. Autoinflammatory syndromes, collectively known as cryopyrinopathies (CAPS), were initially identified as being a direct result of gain of function mutations in the NLRP3 gene. Afterwards, NLRP3 overexpression/overactivation was detected in many peripheral and central nervous system diseases, such as arthritis, gout, atherosclerosis, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. More recently, a great deal of effort has been dedicated to the elucidation of NLRP3 signaling and the discovery of ligands that can inhibit its activation; more than 1300 scientific reports citing NLRP3 have been published over the last year. The main aim of this Special Issue on “Inflammasome Inhibitors” is to collect the latest developments in the design and pharmacological characterization of new NLRP3 ligands. Contributions to this issue, in the form of original research and review articles, are particularly welcome.
Prof. Dr. Massimo Bertinaria
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NLRP3 inflammasome
- NLRP3 inhibitors
- IL-1β blockers
- Pyroptosis
- Inflammation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.